Keflex (Cephalexin) Should NOT Be Used for Acute Otitis Media in Adults
Cephalexin is not an appropriate choice for treating acute otitis media in adults because it lacks adequate activity against Haemophilus influenzae, one of the primary causative pathogens. While the FDA label indicates that Keflex is approved for otitis media 1, this approval is based on older data and does not reflect current understanding of bacterial resistance patterns and treatment failures.
Why Cephalexin Fails in Otitis Media
The H. influenzae Problem
The most compelling evidence against cephalexin comes from multiple studies demonstrating poor efficacy:
- In adults with AOM, H. influenzae accounts for 26% of cases 2, making it the most common bacterial pathogen alongside S. pneumoniae (21%)
- Cephalexin fails in approximately 50% of H. influenzae infections, even when the organism appears sensitive in vitro 3, 4
- Studies from the 1970s-1980s consistently showed treatment failures with cephalexin when H. influenzae was the causative organism 5, 4
What Actually Works
Amoxicillin is the appropriate first-line agent for empiric therapy of acute otitis media in adults 2. The evidence supporting this includes:
- High-dose amoxicillin (80-90 mg/kg/day in children; proportional dosing in adults) targets all three major pathogens: S. pneumoniae, H. influenzae, and M. catarrhalis 6
- The 2017 guideline panel reviewing AOM treatment concluded that amoxicillin may be more effective than cephalosporins and should be considered first-line 7
- Only 22% of H. influenzae isolates and 9% overall produce beta-lactamase in adults 2, meaning standard amoxicillin is usually sufficient
Treatment Algorithm for Adults with AOM
First-line: Amoxicillin 500-875 mg three times daily for 7-10 days
Second-line (if treatment failure or beta-lactamase suspected):
- Amoxicillin-clavulanate
- Cefuroxime axetil
- Cefdinir
- Ceftriaxone
Avoid entirely: Cephalexin, penicillin V, erythromycin, tetracyclines 2 - all lack adequate H. influenzae coverage
Critical Caveats
The FDA label for Keflex lists otitis media as an approved indication 1, but this creates a dangerous disconnect between regulatory approval and clinical evidence. Antimicrobials inactive against H. influenzae are not appropriate for initial therapy 2. The guideline evidence from 2017 7 and research data from 1991 2 both explicitly recommend against first-generation cephalosporins like cephalexin for AOM.
If a patient is already on cephalexin and not improving within 48-72 hours, switch immediately to amoxicillin or amoxicillin-clavulanate rather than continuing ineffective therapy.